|
業務類別
|
Biotechnology |
|
業務概覽
|
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies. |
| 公司地址
| Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123 |
| 電話號碼
| +86 51287773632 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.adagene.com |
| 員工數量
| 128 |
| Dr. John M. Maraganore,PhD |
Executive Advisor |
-- |
01/04/2026 |
| Dr. Axel Hoos, M.D. |
Executive Advisor |
-- |
01/04/2026 |
| Dr. Peter Luo, PhD |
President, R&D, Chairman of the Board and Chief Executive Officer |
-- |
01/04/2026 |
| Dr. Qinghai Zhao, PhD |
Chief Manufacturing Officer |
-- |
01/04/2026 |
| Mr. Man Kin Tam |
Director and Chief Financial Officer |
-- |
01/04/2026 |
| Ms. Yan Li, M.B.A. |
Senior Vice President, Bioinformatics and Information Technology |
-- |
01/04/2026 |
| Ms. Xiaohong She |
Senior Vice President and Head of Clinical Operations |
-- |
01/04/2026 |
| Dr. Guizhong Liu, PhD |
Senior Vice President, Early Drug Discovery |
-- |
01/04/2026 |
| Mr. Alexander Goergen |
Vice President and Head of Business Development |
-- |
01/04/2026 |
| Dr. Songmao Zheng, PhD |
Senior Vice President, Clinical Pharmacology and Quantitative Sciences |
-- |
01/04/2026 |
| Dr. Jiping Zha, M.D. |
Executive Vice President, Clinical Development |
-- |
01/04/2026 |
| Dr. Wenlin Zeng, PhD |
Vice President, Early Stage CMC |
-- |
01/04/2026 |
| Mr. Chane-Du Mickael |
Chief Strategy Officer |
-- |
01/04/2026 |
| Ms. Ling Zhou |
Executive Director of Human Resources |
-- |
01/04/2026 |
| Mr. Chunfang Gu |
Executive Director, Finance |
-- |
01/04/2026 |
|
|
| Mr. Cuong Viet Do |
Independent Director |
01/04/2026 |
| Dr. Li Zhu, PhD |
Independent Director |
01/04/2026 |
| Dr. Peter Luo, PhD |
President, R&D, Chairman of the Board and Chief Executive Officer |
01/04/2026 |
| Mr. Man Kin Tam |
Director and Chief Financial Officer |
01/04/2026 |
| Mr. Andy Cheung |
Independent Director |
01/04/2026 |
| Dr. Ulf Grawunder, PhD |
Independent Director |
01/04/2026 |
|
|
|
|
